AIM ImmunoTech (AIM) Land & Improvements (2018 - 2021)
AIM ImmunoTech's (AIM) quarterly Land & Improvements came in at $3.9 million in Q4 2021, down 63.02% YoY from $10.5 million in Q4 2020, and down 62.96% on a QoQ basis from $10.5 million in Q3 2021.
AIM ImmunoTech (AIM) Land & Improvements (2018 - 2021) Analysis & Trends
AIM ImmunoTech (AIM) has 4 years of Land & Improvements data on file, last reported at $3.9 million in Q4 2021.
- Quarterly Land & Improvements fell 63.02% year-over-year to $3.9 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.9 million (down 63.02% YoY) and the FY2021 annual result came in at $3.9 million, down 63.02% from the prior year.
- Land & Improvements retreated to $3.9 million in Q4 2021, from $10.5 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $10.5 million in Q4 2018 to a low of $3.9 million in Q4 2021.
- A 4-year average of $9.9 million and a median of $10.5 million in 2018 frame the typical range for Land & Improvements.
- Annual changes were most pronounced in 2019 — Land & Improvements changed 0.0% — and 2021, when it tumbled 63.02%.
- Tracing AIM's Land & Improvements over 4 years: stood at $10.5 million in 2018, then changed by 0.0% to $10.5 million in 2019, then changed by 0.0% to $10.5 million in 2020, then plunged by 63.02% to $3.9 million in 2021.
- The last three Land & Improvements figures came in at $3.9 million (Q4 2021), $10.5 million (Q3 2021), and $10.5 million (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 3.90 Mn |
| Sep 30, 2021 | 10.53 Mn |
| Jun 30, 2021 | 10.53 Mn |
| Mar 31, 2021 | 10.55 Mn |
| Dec 31, 2020 | 10.55 Mn |
| Sep 30, 2020 | 10.55 Mn |
| Jun 30, 2020 | 10.55 Mn |
| Mar 31, 2020 | 10.55 Mn |
| Dec 31, 2019 | 10.55 Mn |
| Dec 31, 2018 | 10.55 Mn |